Virus therapy takes on Platinum-Resistant ovarian cancer
NCT ID NCT05271318
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new approach for ovarian cancer that has stopped responding to platinum chemotherapy. It combines TILT-123, a virus engineered to kill cancer cells and boost immune activity, with the immunotherapy drug pembrolizumab, and in some cases also with a chemotherapy called pegylated liposomal doxorubicin. The study enrolls 29 women and primarily aims to check the safety of this combination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TILT-123 (a modified virus that kills cancer cells and boosts the immune system), pembrolizumab (an immunotherapy drug), and pegylated liposomal doxorubicin (a chemotherapy drug)
- What this could lead to
- If this works, it could point toward a new treatment option for ovarian cancer that no longer responds to standard platinum chemotherapy.
- What could go wrong
- This is a very early, small trial (29 people) focused on safety, not effectiveness. The virus and drug combination may cause serious side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-REFRACTORY FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Docrates Cancer Center
Helsinki, 00180, Finland
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Northwell Heatlh/Lenox Hill Hospital
New York, New York, 10075, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to outsmart Chemotherapy-Resistant ovarian cancer
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered immune cells take aim at Hard-to-Treat cancers
- Engineered immune cells take on Hard-to-Treat ovarian and endometrial cancers
- New drug combo aims to prevent deadly bowel blockages in ovarian cancer
- New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches